Skip Navigation LinksHome > August 2013 - Volume 35 - Issue 6 > Iron Chelation With Deferasirox for the Treatment of Seconda...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318292baf5
Original Articles

Iron Chelation With Deferasirox for the Treatment of Secondary Hemosiderosis in Pediatric Oncology Patients: A Single-center Experience

Ktena, Yiouli P. MD; Athanasiadou, Anastasia MD; Lambrou, George MSc; Adamaki, Maria MSc; Moschovi, Maria MD, PhD

Collapse Box

Abstract

Pediatric oncology patients are often iron overloaded, due to the multiple blood transfusions necessary during the course of chemotherapy. Our aim is to report the efficacy and safety of deferasirox, an oral iron chelator, in this patient group. Deferasirox was administered to 13 children with malignancies in remission and iron overload. Ferritin, blood urea nitrogen, creatinine, transaminases, and bilirubin were recorded at 4- to 8-week intervals, and hepatic and cardiac iron overload were assessed with magnetic resonance imaging before initiation of treatment. Deferasirox was administered for an average of 6 months (SD=4.5; range, 0.3 to 18.2). Two children presented with skin rash, 1 with gastrointestinal disturbances, and 1 with fully reversible acute renal failure. The mean monthly rate of change in ferritin levels was −10.8 μg/L before initiation of treatment (95% confidence interval [CI], −19.8 to −1.8; P=0.02) and −93.6 μg/L during deferasirox treatment (95% CI, −118.1 to −69.1; P<0.001). The difference in the monthly rate of change in ferritin levels before and after treatment initiation was −82.8 μg/L (95% CI, −111.6 to −53.9; P<0.001). Deferasirox was effective in reducing the iron burden. The adverse effects were easily monitored and managed. Further studies are warranted to investigate the effect of deferasirox on mortality and morbidity in this population.

Copyright © 2013 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.